Vanguard Personalized Indexing Management
BBIO icon

Vanguard Personalized Indexing Management’s BridgeBio Pharma BBIO Stock Holding History

Vanguard Personalized Indexing Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.23M Sell
16,563
-2,403
-13% -$168K 0.01% 883
2026
Q1 		$1.41M Buy
18,966
+1,727
+10% +$125K 0.01% 762
2025
Q4 		$1.32M Buy
17,239
+436
+3% +$28.6K 0.01% 788
2025
Q3 		$873K Buy
16,803
+625
+4% +$30.5K 0.01% 973
2025
Q2 		$699K Buy
16,178
+772
+5% +$28.1K 0.01% 1050
2025
Q1 		$533K Buy
15,406
+677
+5% +$22.8K 0.01% 1082
2024
Q4 		$404K Buy
14,729
+2,604
+21% +$67.3K 0.01% 1211
2024
Q3 		$309K Buy
12,125
+1,923
+19% +$50.5K 0.01% 1332
2024
Q2 		$258K Buy
10,202
+1,617
+19% +$44.2K ﹤0.01% 1335
2024
Q1 		$265K Buy
8,585
+1,156
+16% +$39.3K 0.01% 1323
2023
Q4 		$300K Buy
+7,429
New +$223K 0.01% 1223
2021
Q3 		– Sell
-4,235
Closed -$258K – 983
2021
Q2 		$258K Buy
+4,235
New +$242K 0.03% 793

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Vanguard Personalized Indexing Management's BBIO Position: Q2 2026 in Review

Vanguard Personalized Indexing Management reduced its BridgeBio Pharma (BBIO) stake by 13% in Q2 2026, selling an estimated $168K and leaving 16,563 shares worth $1.23M. The position accounts for 0.01% of the portfolio, ranked #883.

Vanguard Personalized Indexing Management first reported a position in BBIO in Q2 2021 and has held it in 12 quarters since. The position peaked at $1.41M in Q1 2026. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Vanguard Personalized Indexing Management held 16,563 shares of BridgeBio Pharma worth $1.23M as of Q2 2026.
  • Vanguard Personalized Indexing Management sold 2,403 BridgeBio Pharma shares in Q2 2026, an estimated $168K.
  • BridgeBio Pharma made up 0.01% of Vanguard Personalized Indexing Management's portfolio in Q2 2026, its #883 holding.
  • Vanguard Personalized Indexing Management first reported a position in BridgeBio Pharma in Q2 2021 and has held it in 12 quarters since.
  • Vanguard Personalized Indexing Management's BridgeBio Pharma position peaked at $1.41M in Q1 2026.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Vanguard Personalized Indexing Management's 13F filing for Q2 2026, filed 11 Aug 2026.